問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Urology

Division of Pediatrics

Division of Hematology & Oncology

更新時間:2023-09-19

黃國皓-, -
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -4 個月

篩選

List

64Cases

2026-08-28 - 2032-02-19

Phase III

Not yet recruiting
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY
  • Condition/Disease

    Urothelial Cancer, Urinary Bladder Neoplasms

  • Test Drug

    Enfortumab Vedotin Pembrolizumab

Participate Sites
6Sites

Not yet recruiting6Sites

2016-06-01 - 2024-06-28

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated6Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2021-01-04 - 2026-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2013-09-01 - 2024-03-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2018-10-30 - 2022-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2018-02-05 - 2022-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated9Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-09-28 - 2030-02-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting7Sites

2015-10-01 - 2020-06-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

張牧新
Taipei Veterans General Hospital

Division of Hematology & Oncology

2022-02-01 - 2026-03-30

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2017-05-01 - 2021-09-01

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated4Sites